FINWIRES · TerminalLIVE
FINWIRES

$NEO

9 stories mentioning NEOUpdated 26d ago

Every FINWIRES story that references NEO, newest first.

What are analysts saying about NEO?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on NEO?

Sectors

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks fell late Thursday afternoon, with the NYSE Healthcare Index down 1.2% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 1%.The iShares Biotechnology ETF (IBB) was down 0.1%.In corporate news, Moderna (MRNA) shares dropped 5% after the firm said it plans to offer $2 billion worth of convertible senior notes due 2032 in a private placement.HealthEquity (HQY) shares fell past 10% after the company posted fiscal Q2 results.Novo Nordisk (NVO) said China's National Medical Products Administration has accepted its marketing application for the oral version of its weight-loss drug Wegovy, Reuters reported. Shares were down 2%.NeoGenomics (NEO) shares jumped past 7% after the company said its RaDaR ST molecular residual disease assay received expanded Medicare coverage to include immunotherapy response monitoring for patients with late-stage solid tumors.

$HQY$MRNA$NEO$NVO
Sectors

Sector Update: Healthcare

Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding 1.1%.The iShares Biotechnology ETF (IBB) was down 0.1%.In corporate news, NeoGenomics (NEO) shares jumped nearly 8% after the company said its RaDaR ST molecular residual disease assay received expanded Medicare coverage to include immunotherapy response monitoring for patients with late-stage solid tumors.

$NEO
Wire

Update: NeoGenomics Shares Rise After RaDaR ST Assay Gets Expanded Medicare Coverage

(Updates with the company's latest stock move in the headline and the first paragraph.)NeoGenomics (NEO) shares were up 9% in Thursday trading after the company said its RaDaR ST molecular residual disease assay received expanded Medicare coverage to include immunotherapy response monitoring for patients with late-stage solid tumors.The determination from the Centers for Medicare & Medicaid Services' Molecular Diagnostic Services Program is the third Medicare-covered indication for RaDaR ST, NeoGenomics said Wednesday in a statement.The coverage allows use of the assay to monitor response to immune-checkpoint inhibitor therapy, and NeoGenomics said it has two additional RaDaR ST submissions pending.Price: $18.93, Change: $+1.56, Percent Change: +8.95%

$NEO
Wire

NeoGenomics Wins Expanded Medicare Coverage for RaDaR ST Immunotherapy Monitoring

NeoGenomics (NEO) said its RaDaR ST molecular residual disease assay received expanded Medicare coverage to include immunotherapy response monitoring for patients with late-stage solid tumors.The determination from the Centers for Medicare & Medicaid Services' Molecular Diagnostic Services Program is the third Medicare-covered indication for RaDaR ST, NeoGenomics said Wednesday in a statement.The coverage allows use of the assay to monitor response to immune-checkpoint inhibitor therapy, and NeoGenomics said it has two additional RaDaR ST submissions pending.NeoGenomics shares rose 2.1% in after-hours trading.

$NEO
Wire

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks were lower late Wednesday afternoon, with the NYSE Healthcare Index down 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.8%.The iShares Biotechnology ETF (IBB) shed 0.9%.In corporate news, Hims & Hers Health (HIMS) is being sued by the US Federal Trade Commission, the State of California, and the Utah Division of Consumer Protection, for allegedly sharing users' data with Meta (META), Snap (SNAP) and other online advertising companies, court documents show. Hims & Hers Health shares fell past 14%.UnitedHealth (UNH) may lose significant funding as the Trump administration plans to terminate a Medicare prescription drug subsidy program, The Wall Street Journal reported. The government will end the $3.6 billion subsidy after 2026, which would have directed more than half of its funds to UnitedHealth next year, the report quoted the administration officials as saying. UnitedHealth shares were down 1.8%.Boston Scientific (BSX) lowered its full-year guidance below Wall Street's estimates on Wednesday, citing factors including weak demand for its Watchman heart implant. Its shares were down 1.5%.NeoGenomics (NEO) shares jumped past 15% after it reported better-than-expected Q2 results.

$BSX$HIMS$NEO$UNH
Wire

Sector Update: Healthcare

Healthcare stocks were mixed late Wednesday afternoon, with the NYSE Healthcare Index up 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.4%.The iShares Biotechnology ETF (IBB) eased 0.1%.In corporate news, NeoGenomics (NEO) shares jumped past 17% after it reported better-than-expected Q2 results.

$NEO
Wire

Update: NeoGenomics Shares Rise After Q2 Beat

(Updates with the latest stock movement in the first paragraph and headline.)NeoGenomics (NEO) shares were up over 15% in Wednesday trading following its better-than-expected Q2 results.Late Tuesday, the company reported Q2 adjusted earnings of $0.05 per diluted share, up from $0.03 a year earlier.Analysts polled by FactSet expected $0.03.Revenue for the quarter ended June 30 was $201.7 million, up from 181.3 million a year earlier.Analysts expected $196.9 million.The company said it now expects 2026 revenue of $802 million to $806 million, up from its prior range of $797 million to $803 million. Analysts expect $800.4 million.Price: $15.51, Change: $+2.11, Percent Change: +15.75%

$NEO
Treasury

NeoGenomics Reports Convertible Notes Offering

NeoGenomics (NEO) said late Monday it has launched an offering of $275 million of convertible senior notes due 2032.The company said it plans to grant the initial buyers a 13-day option to buy up to $41.25 million of additional notes.

$NEO
Research

Leerink Upgrades NeoGenomics to Outperform From Market Perform, Adjusts Price Target to $25 From $12

NeoGenomics (NEO) has an average rating of overweight and mean price target of $14.61, according to analysts polled by FactSet.

$NEO

Track with the FINWIRES app suite

FolioX
FolioX
Track NEO in your portfolio
WheelAI
WheelAI
Analyze NEO options with the wheel strategy
StockInsider
StockInsider
See market sentiment on NEO